Takeaways: The decision strengthens Pfizer’s foothold in Canada’s publicly funded pediatric pneumococcal market by making Prevnar 20 the standard for infants in two large provinces, wh...
Takeaways: This approval expands Padcev from later-line urothelial cancer into earlier-stage muscle-invasive bladder cancer, which should broaden Pfizer’s addressable market in Canada and streng...
Takeaways: Ontario’s reimbursement of Braftovi is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
